Thyroid function outcomes after pegylated interferon-α and ribavirin therapy for chronic hepatitis C

Area of Science:

• Hepatology
• Endocrinology
• Clinical Medicine

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern.
• Interferon-alfa (IFN-α) in combination with ribavirin was a standard treatment for hepatitis C.
• Thyroid dysfunction is a known potential side effect of IFN-α therapy.

Purpose of the Study:

• To determine the incidence of new thyroid disease in patients treated for hepatitis C.
• To evaluate thyroid function during the six months following the cessation of interferon-alfa and ribavirin therapy.
• To assess the necessity of ongoing thyroid surveillance post-treatment for hepatitis C.

Main Methods:

• Prospective study of 190 patients treated with interferon-alfa and ribavirin for hepatitis C.
• Thyroid function tests conducted at treatment completion and at 4, 12, and 24 weeks post-treatment.
• Analysis of thyroid disease incidence within a 6-month follow-up period.

Main Results:

• Two cases of thyroid disease were observed among 190 patients (1.0% prevalence) within six months post-therapy.
• One patient developed biphasic thyroiditis, and another presented with primary hypothyroidism.
• The vast majority (99%) of patients maintained normal thyroid function.

Conclusions:

• New-onset thyroid disease is infrequent following interferon-alfa and ribavirin treatment for hepatitis C.
• Routine thyroid surveillance may not be necessary for asymptomatic patients six months post-treatment.
• A single thyroid-stimulating hormone (TSH) measurement at the 6-month follow-up is recommended for asymptomatic individuals.